BeOne Medicines Ltd. (ONC) stock
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/302571% above fair value
$403.60−9.66 (-2.34%)
Close on Nov 18, 2026Market cap $45.89BP/E 72.2Yield –
BeOne Medicines operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
BeOne Medicines's operating income for the twelve months ending Jun 30, 2026 was $923.10M. For fiscal 2025 it was $447.14M. The highest annual figure on record is $447.14M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $447.14M | – |
| FY2024 | Dec 31, 2024 | -$568.20M | – |
| FY2023 | Dec 31, 2023 | -$1.21B | – |
| FY2022 | Dec 31, 2022 | -$1.79B | – |
| FY2021 | Dec 31, 2021 | -$1.44B | – |
| FY2020 | Dec 31, 2020 | -$1.66B | – |
| FY2019 | Dec 31, 2019 | -$959.89M | – |
| FY2018 | Dec 31, 2018 | -$705.77M | – |
| FY2017 | Dec 31, 2017 | -$98.46M | – |
| FY2016 | Dec 31, 2016 | -$117.06M | – |
| FY2015 | Dec 31, 2015 | -$56.75M | – |
| FY2014 | Dec 31, 2014 | -$15.76M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $325.05M | +269.9% |
| Q1 FY2026 | Mar 31, 2026 | $249.90M | +2151.0% |
| Q4 FY2025 | Dec 31, 2025 | $185.04M | – |
| Q3 FY2025 | Sep 30, 2025 | $163.11M | – |
| Q2 FY2025 | Jun 30, 2025 | $87.89M | – |
| Q1 FY2025 | Mar 31, 2025 | $11.10M | – |
| Q4 FY2024 | Dec 31, 2024 | -$79.43M | – |
| Q3 FY2024 | Sep 30, 2024 | -$120.27M | – |
| Q2 FY2024 | Jun 30, 2024 | -$107.16M | – |
| Q1 FY2024 | Mar 31, 2024 | -$261.35M | – |
| Q4 FY2023 | Dec 31, 2023 | -$383.80M | – |
| Q3 FY2023 | Sep 30, 2023 | -$133.97M | – |
| Q2 FY2023 | Jun 30, 2023 | -$318.72M | – |
| Q1 FY2023 | Mar 31, 2023 | -$371.26M | – |
| Q4 FY2022 | Dec 31, 2022 | -$468.62M | – |
| Q3 FY2022 | Sep 30, 2022 | -$438.36M | – |
| Q2 FY2022 | Jun 30, 2022 | -$439.40M | – |
| Q1 FY2022 | Mar 31, 2022 | -$443.29M | -731.8% |
| Q4 FY2021 | Dec 31, 2021 | -$571.74M | – |
| Q3 FY2021 | Sep 30, 2021 | -$462.33M | – |
| Q2 FY2021 | Jun 30, 2021 | -$474.84M | – |
| Q1 FY2021 | Mar 31, 2021 | $70.17M | – |
| Q4 FY2020 | Dec 31, 2020 | -$484.91M | – |
| Q3 FY2020 | Sep 30, 2020 | -$440.14M | – |
| Q2 FY2020 | Jun 30, 2020 | -$358.88M | – |
| Q1 FY2020 | Mar 31, 2020 | -$373.76M | – |
| Q4 FY2019 | Dec 31, 2019 | -$388.04M | – |
| Q3 FY2019 | Sep 30, 2019 | -$312.27M | – |
| Q2 FY2019 | Jun 30, 2019 | -$85.83M | – |
| Q1 FY2019 | Mar 31, 2019 | -$173.76M | – |
| Q4 FY2018 | Dec 31, 2018 | -$280.81M | – |
| Q3 FY2018 | Sep 30, 2018 | -$151.10M | -231.5% |
| Q2 FY2018 | Jun 30, 2018 | -$163.05M | – |
| Q1 FY2018 | Mar 31, 2018 | -$110.81M | – |
| Q4 FY2017 | Dec 31, 2017 | -$103.80M | – |
| Q3 FY2017 | Sep 30, 2017 | $114.91M | – |
| Q2 FY2017 | Jun 30, 2017 | -$58.02M | – |
| Q1 FY2017 | Mar 31, 2017 | -$51.54M | – |
| Q4 FY2016 | Dec 31, 2016 | -$37.27M | – |
| Q3 FY2016 | Sep 30, 2016 | -$34.83M | – |
See a number that looks wrong?